

Research Study Approval

The research study named therein has been approved by the Administration of Radioactive Substances Advisory Committee (ARSAC) for the administrations of radioactive substances there specified as required under Regulation 11(1)(d) of IR(ME)R 2017 (GB) and IR(ME)R 2018 (NI)

Date of Approval: 11/04/2018

Research ID: 48

IRAS ID: 216147

REC Reference: 18/LO/0204

Study Title

A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy

Procedure Code	Nuclide	Chemical
18F-57-169	18F	FDG